Actively Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Led by AbbVie · Updated on 2026-03-11
125
Participants Needed
26
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 125 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 55 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
CONDITIONS
Official Title
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Locally advanced or metastatic solid tumors with confirmed MET amplification by local or central next generation sequencing
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- Measurable disease at baseline according to RECIST v1.1 or RANO criteria
- Prior systemic therapy appropriate for tumor type and stage, with no satisfactory alternative therapy expected to provide substantial survival benefit
- If central nervous system metastases are present, they must be clinically asymptomatic or radiologically stable without progression after treatment
You will not qualify if you...
- Current, past, or suspected non-infectious interstitial lung disease or pneumonitis requiring steroid treatment
- Any major life-threatening conditions
- Life expectancy less than 12 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 26 locations
1
City of Hope National Medical Center /ID# 275613
Duarte, California, United States, 91010
Actively Recruiting
2
Valkyrie Clinical Trials /ID# 275547
Los Angeles, California, United States, 90067
Actively Recruiting
3
Yale University School of Medicine /ID# 275978
New Haven, Connecticut, United States, 06510
Actively Recruiting
4
Florida Cancer Specialists - North /ID# 277137
St. Petersburg, Florida, United States, 33705
Actively Recruiting
5
Northwestern University Feinberg School of Medicine /ID# 276436
Chicago, Illinois, United States, 60611-2927
Actively Recruiting
6
University of Chicago Medical Center /ID# 275342
Chicago, Illinois, United States, 60637
Actively Recruiting
7
START Midwest /ID# 276603
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
8
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999
New York, New York, United States, 10065
Actively Recruiting
9
Duke Cancer Institute /ID# 275604
Durham, North Carolina, United States, 27710
Actively Recruiting
10
The University of Texas MD Anderson Cancer Center /ID# 275663
Houston, Texas, United States, 77030
Actively Recruiting
11
South Texas Accelerated Research Therapeutics (START) /ID# 276608
San Antonio, Texas, United States, 78229
Actively Recruiting
12
Start Mountain Region /ID# 276607
West Valley City, Utah, United States, 84119
Actively Recruiting
13
The Chaim Sheba Medical Center /ID# 274342
Ramat Gan, Tel Aviv, Israel, 5265601
Actively Recruiting
14
Tel Aviv Sourasky Medical Center /ID# 274344
Tel Aviv, Tel Aviv, Israel, 6423906
Actively Recruiting
15
Hadassah Medical Center-Hebrew University /ID# 274343
Jerusalem, Israel, 91120
Actively Recruiting
16
Rabin Medical Center. /ID# 274341
Petah Tikva, Israel, 4941492
Actively Recruiting
17
Nagoya University Hospital /ID# 276336
Nagoya, Aichi-ken, Japan, 466-8560
Actively Recruiting
18
Kyushu University Hospital /ID# 276302
Fukuoka, Fukuoka, Japan, 812-8582
Actively Recruiting
19
Hokkaido University Hospital /ID# 276333
Sapporo, Hokkaido, Japan, 060-8648
Actively Recruiting
20
Kyoto University Hospital /ID# 276398
Kyoto, Kyoto, Japan, 606-8507
Actively Recruiting
21
Tohoku University Hospital /ID# 276344
Sendai, Miyagi, Japan, 980-8574
Actively Recruiting
22
Okayama University Hospital /ID# 276299
Okayama, Okayama-ken, Japan, 700-8558
Actively Recruiting
23
National Cancer Center Hospital /ID# 276297
Chuo-Ku, Tokyo, Japan, 104-0045
Actively Recruiting
24
Seoul National University Hospital /ID# 275703
Seoul, Seoul Teugbyeolsi, South Korea, 03080
Actively Recruiting
25
Yonsei University Health System Severance Hospital /ID# 276184
Seoul, Seoul Teugbyeolsi, South Korea, 03722
Actively Recruiting
26
Samsung Medical Center /ID# 275705
Seoul, Seoul Teugbyeolsi, South Korea, 06351
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here